Invesco Ltd. Has $403,000 Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Invesco Ltd. grew its stake in shares of Cryoport, Inc. (NASDAQ:CYRX) by 11.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 51,803 shares of the company’s stock after purchasing an additional 5,364 shares during the period. Invesco Ltd. owned approximately 0.10% of Cryoport worth $403,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC increased its position in Cryoport by 272.9% in the 3rd quarter. Barclays PLC now owns 81,417 shares of the company’s stock valued at $660,000 after buying an additional 59,582 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Cryoport by 44.8% during the fourth quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock valued at $1,142,000 after acquiring an additional 45,430 shares in the last quarter. Rhumbline Advisers raised its position in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after purchasing an additional 1,764 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Cryoport by 1,464.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company’s stock worth $2,475,000 after purchasing an additional 285,726 shares in the last quarter. Finally, Thrivent Financial for Lutherans bought a new position in shares of Cryoport in the 4th quarter worth $299,000. Institutional investors own 92.90% of the company’s stock.

Insider Buying and Selling

In other news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. The trade was a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 19,830 shares of company stock valued at $118,353 over the last quarter. Corporate insiders own 10.10% of the company’s stock.

Cryoport Price Performance

Shares of Cryoport stock opened at $5.86 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a 52-week low of $4.58 and a 52-week high of $16.89. The company has a fifty day moving average of $5.80 and a 200-day moving average of $6.90. The stock has a market capitalization of $293.80 million, a price-to-earnings ratio of -1.73 and a beta of 1.92.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. During the same period last year, the company posted ($0.29) earnings per share. Equities research analysts expect that Cryoport, Inc. will post -0.99 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. UBS Group upped their price objective on shares of Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. Roth Mkm restated a “buy” rating and issued a $15.00 target price on shares of Cryoport in a report on Tuesday, April 1st. Guggenheim reaffirmed a “buy” rating and issued a $10.00 price target on shares of Cryoport in a research report on Wednesday, April 16th. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.67.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.